Phillip A. Reece

1.2k total citations
36 papers, 886 citations indexed

About

Phillip A. Reece is a scholar working on Molecular Biology, Pharmacology and Pharmacology. According to data from OpenAlex, Phillip A. Reece has authored 36 papers receiving a total of 886 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Pharmacology and 7 papers in Pharmacology. Recurrent topics in Phillip A. Reece's work include Influenza Virus Research Studies (5 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Analytical Methods in Pharmaceuticals (5 papers). Phillip A. Reece is often cited by papers focused on Influenza Virus Research Studies (5 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Analytical Methods in Pharmaceuticals (5 papers). Phillip A. Reece collaborates with scholars based in Australia, United States and United Kingdom. Phillip A. Reece's co-authors include R. Zacest, Allen J. Sedman, Garth Powis, David L. Ahmann, Philip E. Stanley, Raymond G. Morris, Howard N. Bockbrader, S. Rutherfoord Rose, D. Scott Wright and Rukmini Rajagopalan and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Medicinal Chemistry and Life Sciences.

In The Last Decade

Phillip A. Reece

35 papers receiving 822 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Phillip A. Reece Australia 17 246 164 120 110 106 36 886
Keith K. H. Chan United States 22 247 1.0× 185 1.1× 46 0.4× 123 1.1× 220 2.1× 63 1.2k
Ross W. Bury Australia 17 220 0.9× 127 0.8× 70 0.6× 83 0.8× 116 1.1× 32 741
Norbert Knebel Germany 15 303 1.2× 141 0.9× 29 0.2× 81 0.7× 64 0.6× 24 771
Katharine J. Palmer New Zealand 8 200 0.8× 79 0.5× 38 0.3× 107 1.0× 74 0.7× 14 829
Hideyo Noguchi Japan 17 190 0.8× 88 0.5× 37 0.3× 58 0.5× 165 1.6× 55 774
Robert A. Carr United States 19 193 0.8× 191 1.2× 67 0.6× 70 0.6× 92 0.9× 41 986
E Albengres France 19 353 1.4× 203 1.2× 72 0.6× 129 1.2× 252 2.4× 68 986
Nobuo Inotsume Japan 17 212 0.9× 221 1.3× 46 0.4× 159 1.4× 185 1.7× 90 1.1k
J. P. Cano France 16 199 0.8× 319 1.9× 50 0.4× 249 2.3× 123 1.2× 57 1.0k
Julie Ducharme Canada 20 323 1.3× 272 1.7× 53 0.4× 153 1.4× 221 2.1× 45 1.3k

Countries citing papers authored by Phillip A. Reece

Since Specialization
Citations

This map shows the geographic impact of Phillip A. Reece's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip A. Reece with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip A. Reece more than expected).

Fields of papers citing papers by Phillip A. Reece

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip A. Reece. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip A. Reece. The network helps show where Phillip A. Reece may publish in the future.

Co-authorship network of co-authors of Phillip A. Reece

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip A. Reece. A scholar is included among the top collaborators of Phillip A. Reece based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip A. Reece. Phillip A. Reece is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reece, Phillip A.. (2007). Neuraminidase inhibitor resistance in influenza viruses. Journal of Medical Virology. 79(10). 1577–1586. 77 indexed citations
2.
McKimm‐Breschkin, Jennifer L., Peter M. Colman, Betty Jin, et al.. (2003). Tethered Neuraminidase Inhibitors That Bind an Influenza Virus: A First Step Towards a Diagnostic Method for Influenza. Angewandte Chemie. 115(27). 3226–3229. 5 indexed citations
3.
McKimm‐Breschkin, Jennifer L., Peter M. Colman, Betty Jin, et al.. (2003). Tethered Neuraminidase Inhibitors That Bind an Influenza Virus: A First Step Towards a Diagnostic Method for Influenza. Angewandte Chemie International Edition. 42(27). 3118–3121. 23 indexed citations
4.
Allen, Elizabeth, et al.. (1999). Gabapentin Does Not Affect Antipyrine Clearance. The Journal of Clinical Pharmacology. 39(9). 934–935. 3 indexed citations
5.
Forgue, S. Thomas, et al.. (1996). Inhibition of tacrine oral clearance by cimetidine. Clinical Pharmacology & Therapeutics. 59(4). 444–449. 13 indexed citations
6.
Reece, Phillip A., William R. Garnett, John R. Taylor, et al.. (1995). Lack of Effect of Tacrine Administration on the Anticoagulant Activity of Warfarin. The Journal of Clinical Pharmacology. 35(5). 526–528. 3 indexed citations
7.
Sramek, John J., et al.. (1995). Safety and tolerability of CI-979 in patients with alzheimer's disease. Life Sciences. 57(5). 503–510. 26 indexed citations
8.
Reece, Phillip A., et al.. (1994). Diuretic Effects, Pharmacokinetics, and Safety of a New Centrally Acting Kappa‐Opioid Agonist (CI‐977) in Humans. The Journal of Clinical Pharmacology. 34(11). 1126–1132. 64 indexed citations
9.
Blum, Robert A., Thomas J. Comstock, Domenic A. Sica, et al.. (1994). Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clinical Pharmacology & Therapeutics. 56(2). 154–159. 113 indexed citations
10.
Davis, Robert E., C Raby, Michael J. Callahan, et al.. (1993). Chapter 54: Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. Progress in brain research. 98. 439–445. 19 indexed citations
11.
Reece, Phillip A., et al.. (1990). Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion. Cancer Chemotherapy and Pharmacology. 25(4). 274–278. 3 indexed citations
12.
Olver, Ian, Phillip A. Reece, James F. Bishop, et al.. (1990). A Phase I Study of Doxifluridine as a Five-Day Stepped-Dose Continuous Infusion. American Journal of Clinical Oncology. 13(4). 308–311. 2 indexed citations
13.
Bishop, J., et al.. (1989). A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. Cancer Chemotherapy and Pharmacology. 24(4). 246–50. 8 indexed citations
14.
Reece, Phillip A., B.M. Dale, Raymond G. Morris, et al.. (1987). Effect of L-leucine on oral melphalan kinetics in patients. Cancer Chemotherapy and Pharmacology. 20(3). 256–258. 8 indexed citations
15.
Powis, Garth, et al.. (1987). Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemotherapy and Pharmacology. 20(3). 219–222. 92 indexed citations
16.
Reece, Phillip A.. (1981). Hydralazine and related compounds: Chemistry, metabolism, and mode of action. Medicinal Research Reviews. 1(1). 73–96. 58 indexed citations
17.
Reece, Phillip A.. (1980). Quantification of prazosin in plasma by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 221(1). 188–192. 19 indexed citations
18.
Reece, Phillip A., et al.. (1980). Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clinical Pharmacology & Therapeutics. 28(6). 769–778. 45 indexed citations
19.
Reece, Phillip A., Philip E. Stanley, & R. Zacest. (1978). Interference in Assays for Hydralazine in Humans by a Major Plasma Metabolite, Hydralazine Pyruvic Acid Hydrazone. Journal of Pharmaceutical Sciences. 67(8). 1150–1153. 33 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keith K. H. Chan Breakdown of academic impact, for papers by Ross W. Bury Breakdown of academic impact, for papers by Norbert Knebel Breakdown of academic impact, for papers by Katharine J. Palmer Breakdown of academic impact, for papers by Hideyo Noguchi Breakdown of academic impact, for papers by Robert A. Carr Breakdown of academic impact, for papers by E Albengres Breakdown of academic impact, for papers by Nobuo Inotsume Breakdown of academic impact, for papers by J. P. Cano Breakdown of academic impact, for papers by Julie Ducharme
Rankless by CCL
2026